EPC 2021 Updates in Pulmonary Disease
Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology and the Eastern Pulmonary Conference. The American College of Allergy, Asthma and Immunology is accredited by the ACCME to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14.25 contact hours.
This activity is not supported by commercial support.
Target Audience
Practicing allergists, pulmonologists and allied healthcare professionals in the field of allergy, asthma and immunology.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss the role of alarmins in the pathogenesis of asthma and how monoclonal antibodies against alarmins may be of therapeutic benefit.
- Outline how molecular phenotyping of asthma can drive therapeutic decisions
- Discuss the use of oxygen therapy in the critically ill patient: the costs of too much and too little oxygen therapy
- Describe new GINA recommendations regarding the use of short acting beta agonists
- Apply current evidence-based practices to managing uncontrolled asthma
- Explain the clinical presentations, treatments and outcomes of nosocomial pneumonia
- Outline current evidence regarding antibiotic resistance and practical approaches to manage resulting clinical challenges
- Discuss the epidemiology, burden of illness and pathophysiology of pulmonary hypertension and apply new treatment options for this disease
- Explain the recent advances in understanding the natural history and pathogenesis of interstitial lung disease and the use of anti-fibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
- Outline the recent advances in our understanding of biomarkers in the management of COPD
All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:
Sidney Braman, MD – Planner, Moderator, Speaker
Consultant – AstraZeneca
Speaker – Genentech
William Corrao, MD – Moderator, Speaker
Speaker – GlaxoSmithKline, Boehringer Ingelheim
Advisory Board – GlaxoSmithKline
Marilyn Glassberg, MD – Speaker
Advisory Board –Bellerophon, Boehringer Ingelheim, Genentech
Terrill Huggins, MD – Speaker
Author – Up to Date
Barry Make, MD – Speaker
Consultant – AstraZeneca, GlaxoSmithKline, Circassia, Verona, Walters Kluwer, UpToDate, Boehringer Ingelheim, Takeda, Phillips
Speaker – Sunovion
Maria Padilla, MD – Speaker
Consultant – Boehringer Ingelheim, Best Doctors
Speaker – France Foundation, Genentech, Takeda, Paradigm Medical
Author – Up to Date
Panelist – Vindico Medical Education
Rey Panettieri Jr., MD – Planner, Speaker
Speaker – AstraZeneca, Sanofi, Genentech
Consultant – RIFM
Advisory Board - AstraZeneca, MedImmune, Equillium, Theravance, Avillion,
Independent Contractor – AstraZeneca, MedImmune, RIFM, Equillium, Genentech, Theravance, OncoArendi,
Charles Powell, MD – Speaker
Independent Contractor – Alexion
Consultant – Daiichi Sankyo, AstraZeneca, Johnson & Johnson
M. Patricia Rivera, MD – Speaker
Consultant – Johnson & Johnson
Advisory Board – bioAffinity Technologies, Biodesix
Russell Settipane, MD – Planner, Moderator, Speaker, Reviewer
Speaker – ALK, Genentech, Pharming, Regeneron, Shire, Sunovion, Teva, Boehringer Ingelheim
Consultant – Boehringer Ingelheim, RB Health
Advisory Board – ALK, AstraZeneca, Genentech, Regeneron, Sanofi, Teva, Pharming, GlaxoSmithKline
Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Teva, Syneos Health, BioCryst, Avillon
Andy Shorr, MD – Speaker
Speaker – Merck, Tetraphase
Independent Contractor – Merck
Consultant – Merck, Pfizer, Tetraphase, Shionogi
Momen Wahidi, MD – Speaker
Consultant – Olympus, Pulmonx, Cook
Sally Wenzel, MD – Speaker
Consultant – AstraZeneca, Sanofi
Robert Wise, MD – Speaker
Consultant – AstraZeneca, Boehringer Ingelheim, Chiesi, Galderma, GlaxoSmithKline, Merck, Novartis, Kiniksa, Kinevant, Anaptsysbio, PureTech, Contrafect, Kamada, FSD Pharma
DSMB – AbbVie
Independent Contractor – Sanofi
Advisory Board – Chimers, Arrowhead
The following have no relevant financial relationships to disclose:
Sakahi Dua, MD – Speaker
Katelyn Loiselle, RN – Planner
Lawrence Mohr, MD – Speaker
Curt Sessler, MD – Speaker
Ganesh Raghu, MD – Speaker
Ginny Loiselle – Coordinator
Available Credit
- 14.25 AMA PRA Category 1 Credit™
- 14.25 Attendance
- 14.25 CBRN